Showing results (21-30 of 50) with videos related to

Sort By:
Pageof 5
HIV Medicine|January 18, 2008
Regional differences in the risk of triple class failure in European patients starting combination antiretroviral therapy after 1 January 1999A Mocroft, A Horban, B Clotet, et al.
HIV Medicine|April 20, 2016
High frequency of neurosyphilis in HIV-positive patients diagnosed with early syphilisE Firlag-Burkacka, P Swiecki, I Cielniak, et al.
Journal of Viral Hepatitis|October 22, 2013
Seronegative hepatitis C virus infection in patients with lymphoproliferative disordersE Kisiel, M Radkowski, A Pawelczyk, et al.
Sexually Transmitted Infections|March 7, 2015
Clinical and epidemiological characteristics of patients with early syphilis from three academic centres in Poland, Germany and Ireland: initial findings from the POETS studyD Rowley, P Swięcki, E Firlag-Burkacka, et al.
Journal of Viral Hepatitis|October 15, 2013
Hepatitis C virus 5' untranslated region variability correlates with treatment outcomeI Bukowska-Ośko, M Radkowski, A Pawełczyk, et al.
Przeglad Epidemiologiczny|January 1, 1996
[Initial evaluation of the diagnostic usefulness of tuberculin tests among the patients of the Center of Diagnosis and Treatment of AIDS]A Zieliński, G Cholewińska, B Wondołowska, et al.
The Journal of Infectious Diseases|November 6, 2004
Time to virological failure of 3 classes of antiretrovirals after initiation of highly active antiretroviral therapy: results from the EuroSIDA study groupA Mocroft, B Ledergerber, J P Viard, et al.
Przeglad Epidemiologiczny|January 1, 1996
[Initial assessment of the use of polymerase chain reaction (PCR) in diagnosis of tuberculosis among patients of the Center for Diagnosis and Treatment of AIDS]A Zieliński, G Cholewińska, B Wondołowska, et al.
Infection|August 10, 2006
Opportunistic infections and other AIDS-defining illnesses in Poland in 2000-2002R B Podlasin, A Wiercinska-Drapalo, A Olczak, et al.
HIV Medicine|April 6, 2005
Comparison of gastrointestinal tolerability and patient preference for treatment with the 625 mg and 250 mg nelfinavir tablet formulationsM Johnson, L Nieto-Cisneros, A Horban, et al.
Pageof 5